A phase 1b study of trebananib plus paclitaxel (P) and trastuzumab (T) in patients (pts) with HER2+locally recurrent or metastatic breast cancer (MEW).

被引：0
|
作者：
Kaufman, Peter Andrew
Freyer, Gilles
Kemeny, Margaret
Goncalves, Anthony
Heinrich, Guy
Jerusalem, Maria
Stopeck, Alison
Vrindavanam, Nandagopal
Dalenc, Florence
Nanayakkara, Nuwan
Wu, Benjamin
Pickett-Gies, Cheryl Ann
Wildiers, Hans
机构：
[1] Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03766 USA
[2] Ctr Hosp Lyon Sud, Lyon, France
[3] Queens Hosp, Queens Canc Ctr, Jamaica, NY USA
[4] Inst Paoli Calmettes, Marseille, France
[5] Ctr Hosp Univ Sart Tilman Liege, Liege, Belgium
[6] Univ Liege, Liege, Belgium
[7] Univ Arizona, Ctr Canc, Tucson, AZ USA
[8] Signal Point Hem Onc, Middletown, OH USA
[9] Inst Claudius Regaud, Toulouse, France
[10] Quintiles, San Diego, CA USA
[11] Amgen Inc, Dept Pharmacokinet & Drug Metab, Thousand Oaks, CA 91320 USA
[12] Amgen Inc, Oncol Clin Dev, Thousand Oaks, CA 91320 USA
[13] Univ Hosp Leuven, Leuven, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.502
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
502
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I study of dasatinib in combination with trastuzumab and paclitaxel in patients with HER2 positive metastatic breast cancer
    Gil, M.
    Martin, M.
    Antolin, S.
    Trigo, J. M.
    Guerrero, A.
    Vidal, L.
    Urruticoechea, A.
    Pandiella, A.
    Hernando, A.
    Ocana, A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S180 - S180
  • [32] Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial
    Goel, Shom
    Pernas, Sonia
    Tan-Wasielewski, Zhenying
    Barry, William T.
    Bardia, Aditya
    Rees, Rebecca
    Andrews, Chelsea
    Tahara, Rie Kawabori
    Trippa, Lorenzo
    Mayer, Erica L.
    Winer, Eric P.
    Spring, Laura M.
    Tolaney, Sara M.
    CLINICAL BREAST CANCER, 2019, 19 (06) : 399 - 404
  • [33] Phase 1b trial of cirmtuzumab and paclitaxel for locally advanced, unresectable and metastatic breast cancer.
    Shatsky, Rebecca
    Messer, Karen
    Helsten, Teresa L.
    Schwab, Richard B.
    Pittman, Emily I.
    Chen, Ruifeng
    Weihe, Elizabeth
    Widhopf, George
    Ghia, Emmanuela M.
    Rassenti, Laura Z.
    Alfred, Molinolo A.
    Breitmeyer, James
    Jamieson, Catriona H.
    Kipps, Thomas J.
    Parker, Barbara A.
    CANCER RESEARCH, 2021, 81 (13)
  • [34] Phase 1b/2 trial of the HER3 inhibitor patritumab (U3-1287) in combination with trastuzumab plus paclitaxel in newly-diagnosed patients with HER2+metastatic breast cancer (MBC)
    Carraro, S.
    Campos, D.
    Copigneaux, C.
    Saintilien, C.
    Beckman, R. A.
    Korbenfeld, E.
    Coppola, M. P.
    Halabe, K.
    Cazap, E.
    CANCER RESEARCH, 2013, 73
  • [35] Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer
    Robert, Nicholas
    Leyland-Jones, Brian
    Asmar, Lina
    Belt, Robert
    Ilegbodu, Des
    Loesch, David
    Raju, Robert
    Valentine, Elizabeth
    Sayre, Robert
    Cobleigh, Melody
    Albain, Kathy
    McCullough, Cecelia
    Fuchs, Lea
    Slamon, Dennis
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2786 - 2792
  • [36] A feasibility-phase II study evaluating cardiotoxicity of weekly trastuzumab(T) plus epirubicin(E) and paclitaxel(P) for HER-2 positive locally advanced(LA) and/or metastatic(M) breast cancer(BC)
    Nistico, Cecilia
    Bria, Emilio
    Cuppone, Federica
    Carpino, Armando
    Sperduti, Isabella
    Toglia, Giuseppe
    Vaccaro, Vanja
    Barberi, Simona
    Giannarelli, Diana
    Cognetti, Francesco
    Terzoli, Edmondo
    ANNALS OF ONCOLOGY, 2007, 18 : 42 - 42
  • [37] Trial in progress: A phase 1b/2 study of the PARP inhibitor niraparib in combination with trastuzumab in patients with metastatic HER2+breast cancer (TBCRC 050).
    Stringer-Reasor, Erica Michelle
    Li, Yufeng
    Witherspoon, Felicia
    Specht, Jennifer M.
    Mesias, Jesus Del Santo Anampa
    Nanda, Rita
    Dees, Elizabeth Claire
    Wolff, Antonio C.
    Krop, Ian E.
    Lin, Nancy U.
    Rimawi, Mothaffar F.
    Yang, Eddy Shih-Hsin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for HER2+locally recurrent or metastatic breast cancer (MBC): Results from a phase II, single-arm, multicenter study.
    Puhalla, Shannon
    Wilks, Sharon
    Brufsky, Adam
    O'Shaughnessy, Joyce
    Schwartzberg, Lee Steven
    Berrak, Erhan
    Song, James
    Cox, David
    Vandat, Linda T.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [39] Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC)
    Datko, Farrah Mikhail
    D'Andrea, Gabriella
    Dickler, Maura N.
    Theodoulou, Maria
    Goldfarb, Shari Beth
    Lake, Diana
    Fornier, Monica Nancy
    Modi, Shanu
    Sklarin, Nancy T.
    Comen, Elizabeth Anne
    Fasano, Julie
    Gajria, Devika
    Drullinsky, Pamela
    Murphy, Conleth G.
    Syldor, Angemael
    Patil, Sujata
    Liu, Jennifer
    Chandarlapaty, Sarat
    Hudis, Clifford
    Dang, Chau T.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [40] Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC).
    Datko, Farrah Mikhail
    D'Andrea, Gabriella
    Dickler, Maura N.
    Goldfarb, Shari Beth
    Theodoulou, Maria
    Lake, Diana
    Fornier, Monica Nancy
    Modi, Shanu
    Fasano, Julie
    Comen, Elizabeth Anne
    Gajria, Devika
    Moynahan, Mary Ellen
    Traina, Tiffany A.
    Chen, Melanie
    Hamilton, Nicola
    Patil, Sujata
    Chandarlapaty, Sarat
    Hudis, Clifford
    Dang, Chau T.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345